VentriPoint Building European Network of Reference Centres for VMS™
SEATTLE, WASHINGTON–(Marketwire – May 25, 2012) – VentriPoint Diagnostics Ltd. (TSX VENTURE:VPT) (OTCQX:VPTDF) has installed its VMS™ heart analysis system at University Children’s Hospital in Zurich, Switzerland for their Congenital Heart Disease clinics.
“With the implementation of VMS™, we complete the spectrum of imaging modalities that we can offer to our patients. We will use the system in patients with repaired Tetralogy of Fallot, a population in which our group has a longstanding and successful experience, both in clinical practice and advancing technology through research. We will expand the clinical use of VMS™ for evaluation of patients with transposition of the great arteries and atrial repair, through the involvement of our adult congenital heart disease clinic. VMS™ will save us time and effort in managing our congenital heart disease patients,” stated Dr. Emanuela Valsangiacomo-Büchel, Cardiologist at the University Children’s Hospital.
The division of Pediatric Cardiology at University Children’s Hospital in Zurich is the largest division in Switzerland taking care of Children with CHD, and provides the entire spectrum of subspecialties in the field.
“With VMS™ heart analysis systems in the United Kingdom, Norway, Netherlands and now Switzerland, we are rapidly building a network of reference centres in Europe where interested cardiologists can go to use the VMS™ prior to acquiring one for their own hospitals”, said Dr. George Adams, CEO of VentriPoint.
The VMS™ is for investigational use only in the United States and is approved for sale and clinical use in Canada and Europe.
About VentriPoint Diagnostics Ltd.
VentriPoint has created a diagnostic ultrasound tool to monitor patients with heart disease, a leading cause of death in developed countries. Management believes the VMS™ is the first cost-effective and accurate diagnostic tool for measuring right ventricle heart function. Congenital heart disease is the first application in a suite of applications for all major heart diseases including pulmonary hypertension, cardiovascular disease and heart failure, which management believes has a multibillion-dollar market potential. Canada and Europe (CE Mark) have granted approval for the sale of VentriPoint’s VMS™ heart analysis system and VentriPoint is pursuing the US-FDA approval through the 510(k) process.
FORWARD-LOOKING STATEMENTS: The statements made in this press release that are not historical facts contain forward-looking information that involves risk and uncertainties. All statements, other than statements of historical facts, which address VentriPoint’s expectations, should be considered forward-looking statements. Such statements are based on management’s exercise of business judgment as well as assumptions made by and information currently available to management. When used in this document, the words “may”, “will”, “anticipate”, “believe”, “estimate”, “expect”, “intend” and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements reflect a current view of future events and are subject to certain risks and uncertainties as contained in the Corporation’s filings with Canadian securities regulatory authorities. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in these forward-looking statements. These forward-looking statements are made as of the date of this press release and, other than as required by applicable securities laws, the Corporation does not assume any obligation to update or revise them to reflect new events or circumstances. Although management believes that expectations are based on reasonable assumptions, no assurance can be given that these expectations will materialize.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Howard Group Inc.
1.888-221-0915 or 403-221-0915